Herpes zoster infection
- Overview
- Theory
- Diagnosis
- Management
- Follow up
- Resources
Treatment algorithm
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
acute symptoms: immunocompetent
oral antiviral therapy
Antivirals shorten the duration of viral shedding, stop the formation of new lesions, and reduce pain severity. Treatment is usually with orally administered antiviral medicines such as aciclovir, famciclovir, and valaciclovir. Start within 48 to 72 hours of rash onset and administer for 7 days (up to 10 days in patients with eye manifestations). A systematic review of high-quality trials has found that famciclovir and valacyclovir were superior to acyclovir in reducing the likelihood of prolonged pain.[84]McDonald EM, de Kock J, Ram FS. Antivirals for management of herpes zoster including ophthalmicus: a systematic review of high-quality randomized controlled trials. Antivir Ther. 2012;17(2):255-64. http://www.ncbi.nlm.nih.gov/pubmed/22300753?tool=bestpractice.com
Primary options
famciclovir: 500 mg orally every 8 hours for 7 days
OR
valaciclovir: 1000 mg orally every 8 hours for 7 days
Secondary options
aciclovir: 800 mg orally five times daily for 7-10 days; 10 mg/kg intravenously every 8 hours for 7 days
simple analgesics ± calamine lotion
Treatment recommended for ALL patients in selected patient group
The type of analgesics administered will depend on the severity of the pain.
Primary options
paracetamol: 500-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day
OR
ibuprofen: 200-400 mg orally every 4-6 hours when required, maximum 2400 mg/day
Secondary options
paracetamol: 500-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day
or
ibuprofen: 200-400 mg orally every 4-6 hours when required, maximum 2400 mg/day
-- AND --
calamine lotion topical: apply to the affected area(s) up to four times daily when required
opioid analgesics ± topical analgesic
Additional treatment recommended for SOME patients in selected patient group
The type of analgesics administered will depend on the severity of pain.
Primary options
oxycodone: 5 mg orally (immediate-release) every 4-6 hours when required
Secondary options
oxycodone: 5 mg orally (immediate-release) every 4-6 hours when required
-- AND --
lidocaine topical: (5% ointment) apply to the affected area(s) two to three times daily when required
or
calamine lotion topical: apply to the affected area(s) up to four times daily when required
prompt referral to ophthalmologist
Treatment recommended for ALL patients in selected patient group
Prompt referral to an ophthalmologist is required for all patients who have eye manifestations.[3]Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007 Jan 1;44 Suppl 1:S1-26. https://academic.oup.com/cid/article/44/Supplement_1/S1/334966 http://www.ncbi.nlm.nih.gov/pubmed/17143845?tool=bestpractice.com
Treatment includes the use of antiviral drugs such as aciclovir, famciclovir, or valaciclovir for 7 to 10 days, preferably started within 72 hours of rash onset. Intravenous aciclovir is given as needed for retinitis. Oral antiviral drugs resolve acute disease and inhibit late inflammatory recurrences.[82]Severson EA, Baratz KH, Hodge DO, et al. Herpes zoster ophthalmicus in Olmsted County, Minnesota: have systemic antivirals made a difference? Arch Ophthalmol. 2003 Mar;121(3):386-90. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/415180 http://www.ncbi.nlm.nih.gov/pubmed/12617710?tool=bestpractice.com [115]Tyring S, Engst R, Corriveau C, et al. Famciclovir for ophthalmic zoster: a randomised aciclovir controlled study. Br J Ophthalmol. 2001 May;85(5):576-81. http://www.ncbi.nlm.nih.gov/pubmed/11316720?tool=bestpractice.com Other treatment includes pain medicines, antibiotic ophthalmic ointment to protect the ocular surface, and topical corticosteroids. Systemic corticosteroids may be indicated in moderate-to-severe pain, especially if there is oedema surrounding the orbital area.[3]Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007 Jan 1;44 Suppl 1:S1-26. https://academic.oup.com/cid/article/44/Supplement_1/S1/334966 http://www.ncbi.nlm.nih.gov/pubmed/17143845?tool=bestpractice.com
Therapy for chronic problems includes the following: lubricating, preservative-free artificial tear gels or tears; antibiotic ointment; lateral tarsorrhaphy to protect the corneas (which are often hypoaesthetic/anaesthetic as a result of neuronal damage) from breakdown; continuous-wear, therapeutic soft contact lenses and antibiotic drops; topical corticosteroids and antibiotics for inflammatory disease (iritis, episcleritis, scleritis, and immune keratitis); dilation for iritis; glaucoma therapy as needed.
Surgical management as needed: for example, for amniotic membrane transplantation, tissue-adhesive seal ulcers, keratoprosthesis, and glaucoma trabeculectomy. Chronic pain management is generally similar to that for postherpetic neuralgia.[3]Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007 Jan 1;44 Suppl 1:S1-26. https://academic.oup.com/cid/article/44/Supplement_1/S1/334966 http://www.ncbi.nlm.nih.gov/pubmed/17143845?tool=bestpractice.com
acute symptoms: immunocompromised
oral antiviral therapy
Immunocompromised patients should promptly receive antiviral therapy within 1 week of rash onset or any time before full crusting of lesions. Localised disease should be treated with oral valaciclovir, famciclovir, or aciclovir, with close outpatient follow-up.
Primary options
aciclovir: 800 mg orally five times daily for 7-10 days; 10 mg/kg intravenously every 8 hours for 7 days
OR
famciclovir: 500 mg orally every 8 hours for 7 days
OR
valaciclovir: 1000 mg orally every 8 hours for 7 days
simple analgesics ± calamine lotion
Treatment recommended for ALL patients in selected patient group
The type of analgesics administered will depend on the severity of the pain.
Primary options
paracetamol: 500-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day
OR
ibuprofen: 200-400 mg orally every 4-6 hours when required, maximum 2400 mg/day
Secondary options
paracetamol: 500-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day
or
ibuprofen: 200-400 mg orally every 4-6 hours when required, maximum 2400 mg/day
-- AND --
calamine lotion topical: apply to the affected area(s) up to four times daily when required
opioid analgesics ± topical analgesic
Additional treatment recommended for SOME patients in selected patient group
The type of analgesics administered will depend on the severity of pain.
Primary options
oxycodone: 5 mg orally (immediate-release) every 4-6 hours when required
Secondary options
oxycodone: 5 mg orally (immediate-release) every 4-6 hours when required
-- AND --
lidocaine topical: (5% ointment) apply to the affected area(s) two to three times daily when required
or
calamine lotion topical: apply to the affected area(s) up to four times daily when required
intravenous aciclovir
If the patient is unable to tolerate oral medication, intravenous aciclovir can be given.
Primary options
aciclovir: 10 mg/kg intravenously every 8 hours for 7 days
simple analgesics ± calamine lotion
Treatment recommended for ALL patients in selected patient group
The type of analgesics administered will depend on the severity of the pain.
Primary options
paracetamol: oral/rectal: 500-1000 mg orally/rectally every 4-6 hours when required, maximum 4000 mg/day; intravenous (<50 kg body weight): 15 mg/kg intravenously every 4-6 hours when required, maximum 60 mg/kg/day; intravenous (≥50 kg body weight): 1000 mg intravenously every 4-6 hours when required, maximum 4000 mg/day (3000 mg/day if risk factors for hepatotoxicity)
OR
diclofenac sodium: 37.5 mg intravenously every 6 hours when required, maximum 150 mg/day
Secondary options
paracetamol: oral/rectal: 500-1000 mg orally/rectally every 4-6 hours when required, maximum 4000 mg/day; intravenous (<50 kg body weight): 15 mg/kg intravenously every 4-6 hours when required, maximum 60 mg/kg/day; intravenous (≥50 kg body weight): 1000 mg intravenously every 4-6 hours when required, maximum 4000 mg/day (3000 mg/day if risk factors for hepatotoxicity)
or
diclofenac sodium: 37.5 mg intravenously every 6 hours when required, maximum 150 mg/day
-- AND --
calamine lotion topical: apply to the affected area(s) up to four times daily when required
opioid analgesics ± topical analgesic
Additional treatment recommended for SOME patients in selected patient group
The type of analgesics administered will depend on the severity of pain.
Primary options
oxycodone: 5 mg orally (immediate-release) every 4-6 hours when required
Secondary options
oxycodone: 5 mg orally (immediate-release) every 4-6 hours when required
-- AND --
lidocaine topical: (5% ointment) apply to the affected area(s) two to three times daily when required
or
calamine lotion topical: apply to the affected area(s) up to four times daily when required
intravenous aciclovir
Intravenous aciclovir therapy should be reserved for patients with disseminated infection, ophthalmic involvement, or very severe immunosuppression.
Primary options
aciclovir: 10 mg/kg intravenously every 8 hours for 7 days
opioid analgesics ± topical analgesic
Additional treatment recommended for SOME patients in selected patient group
The type of analgesics administered will depend on the severity of pain.
Primary options
oxycodone: 5 mg orally (immediate-release) every 4-6 hours when required
Secondary options
oxycodone: 5 mg orally (immediate-release) every 4-6 hours when required
-- AND --
lidocaine topical: (5% ointment) apply to the affected area(s) two to three times daily when required
or
calamine lotion topical: apply to the affected area(s) up to four times daily when required
postherpetic pain
paracetamol or NSAID
Patients with mild-to-moderate pain should be treated with non-steroidal anti-inflammatory drugs (NSAIDs) or paracetamol, alone or in combination with a weak opioid analgesic.[100]Wu CL, Marsh A, Dworkin RH. The role of sympathetic nerve blocks in herpes zoster and postherpetic neuralgia. Pain. 2000 Aug;87(2):121-9. http://www.ncbi.nlm.nih.gov/pubmed/10924805?tool=bestpractice.com [101]Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998 Dec 2;280(21):1837-42. https://jamanetwork.com/journals/jama/fullarticle/188226 http://www.ncbi.nlm.nih.gov/pubmed/9846778?tool=bestpractice.com [102]Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology. 1998 Jun;50(6):1837-41. http://www.ncbi.nlm.nih.gov/pubmed/9633737?tool=bestpractice.com [103]Bernstein JE, Korman NJ, Bickers DR, et al. Topical capsaicin treatment of chronic postherpetic neuralgia. J Am Acad Dermatol. 1989 Aug;21(2 Pt 1):265-70. http://www.ncbi.nlm.nih.gov/pubmed/2768576?tool=bestpractice.com [104]Galer BS, Rowbotham MC, Perander J, et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain. 1999 Apr;80(3):533-8. http://www.ncbi.nlm.nih.gov/pubmed/10342414?tool=bestpractice.com
Primary options
paracetamol: 500-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day
OR
ibuprofen: 200-400 mg orally every 4-6 hours when required, maximum 2400 mg/day
weak opioid analgesic
Additional treatment recommended for SOME patients in selected patient group
Patients with mild-to-moderate pain should be treated with non-steroidal anti-inflammatory drugs or paracetamol, alone or in combination with a weak opioid analgesic.[100]Wu CL, Marsh A, Dworkin RH. The role of sympathetic nerve blocks in herpes zoster and postherpetic neuralgia. Pain. 2000 Aug;87(2):121-9. http://www.ncbi.nlm.nih.gov/pubmed/10924805?tool=bestpractice.com [101]Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998 Dec 2;280(21):1837-42. https://jamanetwork.com/journals/jama/fullarticle/188226 http://www.ncbi.nlm.nih.gov/pubmed/9846778?tool=bestpractice.com [102]Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology. 1998 Jun;50(6):1837-41. http://www.ncbi.nlm.nih.gov/pubmed/9633737?tool=bestpractice.com [103]Bernstein JE, Korman NJ, Bickers DR, et al. Topical capsaicin treatment of chronic postherpetic neuralgia. J Am Acad Dermatol. 1989 Aug;21(2 Pt 1):265-70. http://www.ncbi.nlm.nih.gov/pubmed/2768576?tool=bestpractice.com [104]Galer BS, Rowbotham MC, Perander J, et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain. 1999 Apr;80(3):533-8. http://www.ncbi.nlm.nih.gov/pubmed/10342414?tool=bestpractice.com
Primary options
codeine phosphate: 15-60 mg orally every 4-6 hours when required, maximum 240 mg/day
topical capsaicin
Topical capsaicin has also been shown to provide pain relief.[105]Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 2008 Dec;7(12):1106-12. http://www.ncbi.nlm.nih.gov/pubmed/18977178?tool=bestpractice.com [106]Derry S, Rice AS, Cole P, et al. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017 Jan 13;(1):CD007393. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007393.pub4/full http://www.ncbi.nlm.nih.gov/pubmed/28085183?tool=bestpractice.com [107]Irving GA, Backonja MM, Dunteman E, et al. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med. 2011 Jan;12(1):99-109. http://www.ncbi.nlm.nih.gov/pubmed/21087403?tool=bestpractice.com [108]Webster LR, Malan TP, Tuchman MM, et al. A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. J Pain. 2010 Oct;11(10):972-82. http://www.ncbi.nlm.nih.gov/pubmed/20655809?tool=bestpractice.com
Primary options
capsaicin topical: (0.025 to 0.075%) apply to the affected area(s) three to four times daily
strong opioid, amitriptyline, or anticonvulsant
For patients with moderate-to-severe pain, a strong opioid analgesic may be considered. Treatment with either a tricyclic antidepressant such as amitriptyline or an anticonvulsant such as gabapentin or pregabalin is also effective.[109]Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005454.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005454.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/17943857?tool=bestpractice.com
[110]Roth TV, van Seventer R, Murphy TK. The effect of pregabalin on pain-related sleep interference in diabetic peripheral neuropathy or postherpetic neuralgia: a review of nine clinical trials. Cur Med Res Op. 2010 Oct;26(10):2411-9.
http://www.ncbi.nlm.nih.gov/pubmed/20812792?tool=bestpractice.com
[111]Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017 Jun 9;(6):CD007938.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007938.pub4/full
http://www.ncbi.nlm.nih.gov/pubmed/28597471?tool=bestpractice.com
[112]Semel D, Murphy TK, Zlateva G, et al. Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. BMC Fam Pract. 2010 Nov 5;11:85.
https://bmcfampract.biomedcentral.com/articles/10.1186/1471-2296-11-85
http://www.ncbi.nlm.nih.gov/pubmed/21054853?tool=bestpractice.com
[ ]
For adults with postherpetic neuralgia, how does pregabalin compare with placebo?/cca.html?targetUrl=https://www.cochranelibrary.com/cca/doi/10.1002/cca.2480/fullShow me the answer
[
]
What are the effects of gabapentin in adults with chronic neuropathic pain?/cca.html?targetUrl=https://www.cochranelibrary.com/cca/doi/10.1002/cca.2525/fullShow me the answer One meta-analysis showed no difference in pain relief between gabapentin and tricyclic antidepressants.[113]Chou R, Carson S, Chan BK. Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials. J Gen Intern Med. 2009 Feb;24(2):178-88.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2628998
http://www.ncbi.nlm.nih.gov/pubmed/19089502?tool=bestpractice.com
For those intolerant of opioids or at high risk of addiction, one or a combination of anticonvulsants, tricyclic antidepressants, or corticosteroids is appropriate.
Primary options
tramadol: 50-100 mg orally every 4-6 hours when required, maximum 400 mg/day
OR
oxycodone: 5 mg orally (immediate-release) every 4-6 hours when required
Secondary options
amitriptyline: 0.5 to 2 mg/kg orally once daily at bedtime initially, increase according to response, maximum 150 mg/day
OR
gabapentin: 300 mg orally three times daily initially, increase according to response, maximum 1800 mg/day
OR
pregabalin: 300 mg/day orally given in 2-3 divided doses
Choose a patient group to see our recommendations
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer
Use of this content is subject to our disclaimer